登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603222 证券简称：济民健康 公告编号：2026-006 济民健康管理股份有限公司 关于回购公司股份比例达2%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2026年2月27日，公司通过集中竞价交易方式累计回购股份10,626,840股，占公司总股本的比例为 2.02%，购买的最高价为9.75元/股，最低价为5.87元/股，已支付的总金额为90,962,358.7元（不含交易费 用）。 其中2026年2月，公司通过集中竞价交易方式回购股份5,286,560股，回购股份占公司总股本的比例为 1.01%，成交的最高价为9.63元/股，最低价为8.95元/股，支付的总金额为48,876,806.4元（不含交易费 用）。上述回购符合相关法律法规的规定及公司既定的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决 ...

（文章来源：证券日报） 证券日报网讯 2月27日，济民健康发布公告称，截至2026年2月27日，公司通过集中竞价交易方式累计 回购股份10，626，840股，占公司总股本的比例为2.02%。其中2026年2月，公司通过集中竞价交易方 式回购股份5，286，560股，占公司总股本的比例为1.01%。 ...

格隆汇2月27日丨济民健康(603222.SH)公布，截至2026年2月27日，公司通过集中竞价交易方式累计回 购股份1062.68万股，占公司总股本的比例为2.02%，购买的最高价为9.75元/股，最低价为5.87元/股，已 支付的总金额为9096.24万元（不含交易费用）。 ...

证券代码：603222 证券简称：济民健康 公告编号：2026-007 济民健康管理股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股 | 32,219.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 21.76 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担 | | | 保 | | 其他风险提示（如有） | 无 | 一、担保情况概述 ...

| 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,062.68万股 | | 累计已回购股数占总股本比例 | 2.02% | | 累计已回购金额 | 9,096.24万元 | | 实际回购价格区间 | 5.87元/股~9.75元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容 ...

资料显示，济民健康管理股份有限公司位于浙江省台州市黄岩区北院路888号，成立日期1996年12月24 日，上市日期2015年2月17日，公司主营业务涉及医疗器械的研发、生产和销售,医疗服务,以及大输液产 品研发、生产和销售。主营业务收入构成为：医药制造52.07%，医疗服务46.01%，医药贸易1.54%，其 他(补充)0.38%。 截至9月30日，济民健康股东户数5.81万，较上期增加107.00%；人均流通股9035股，较上期减少 51.69%。2025年1月-9月，济民健康实现营业收入5.45亿元，同比减少20.21%；归母净利润-7715.04万 元，同比减少371.51%。 2月25日，济民健康涨1.68%，成交额7577.07万元。两融数据显示，当日济民健康获融资买入额400.17 万元，融资偿还379.04万元，融资净买入21.13万元。截至2月25日，济民健康融资融券余额合计1.69亿 元。 融资方面，济民健康当日融资买入400.17万元。当前融资余额1.69亿元，占流通市值的3.55%，融资余 额低于近一年20%分位水平，处于低位。 融券方面，济民健康2月25日融券偿还0.00股，融券卖出3 ...

Industry and Company Overview - The medical consumables sector showed a slight increase, with the sector index closing at 6067.61 points, up by 0.35% [2] - The performance of leading companies in the medical consumables sector included Maipu Medical (+8.5%), Hualan Biological (+7.5%), and Zhend Medical (+6.7%), while underperformers included Microelectrophysiology (-2.9%) and Daobo Medical (-3%) [2] Market Valuation Metrics - As of February 6, the medical consumables sector had a PE ratio of 36.1X, down by 0.23X from the previous week, with a one-year high of 40.1X and a low of 28.88X; the PB ratio was 2.61X, with a one-year high of 2.92X and a low of 2.13X [4] Recent Developments - Microelectrophysiology's product, a disposable intracardiac ultrasound imaging catheter, has been approved for market release, enhancing its core product offerings in cardiac intervention and filling a gap in integrated ultrasound imaging and electrophysiological mapping solutions [5] Investment Recommendations - There is a high certainty of continued performance recovery for some high-value consumable companies, driven by recent approvals of innovative products and overseas business development, which are expected to create new growth points outside of centralized procurement [6] - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the orthopedic implants, cardiovascular intervention devices, and neurosurgical implants sectors, as well as those with advantages in rehabilitation and chronic disease management [6][7]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

Group 1 - The company has appointed Tianjian Accounting Firm as the auditor for its 2025 financial statements and internal control audits [1][2] - The signing auditors have changed due to internal adjustments at Tianjian, with Wang Chao replacing Peng Haowei [2] - Wang Chao has been engaged in auditing since 2017 and became a certified public accountant in April 2021 [3] Group 2 - Wang Chao has no criminal or administrative penalties in the past three years [4] - The new signing auditor meets the independence requirements as per the Code of Ethics for Chinese Certified Public Accountants [5] - The change in signing auditors will not affect the audit work for the company's 2025 financial statements and internal controls [6] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between RMB 100 million and RMB 200 million [9] - As of January 30, 2026, the company has repurchased 5,340,280 shares, accounting for 1.02% of the total share capital, with a total expenditure of approximately RMB 42.09 million [9][10] - In January 2026, the company repurchased 2,279,780 shares, representing 0.43% of the total share capital, with a total expenditure of approximately RMB 20.10 million [10]

Group 1 - The company Jimin Health announced a change in its signing registered accountants to Lai Xingkai and Wang Chao [2]